- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01665950
Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Primary Aim: To estimate the antidepressant efficacy of simvastatin versus placebo as an adjunct to lithium, valproate, and/or other atypical antipsychotic therapy among individuals with bipolar I disorder in a nonpsychotic major depressive episode.
Hypothesis: Simvastatin will be superior to placebo in improvement of depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale (MADRS).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion:
- Age 18-65
- written informed consent
- meets Diagnostic and Statistical Manual - IV (DSM-IV) criteria (by Structured Clinical Interview for DSM-IV (SCID-I/P)) for bipolar I disorder, current episode depressed
- Montgomery-Asberg Depression Scale (MADRS) score of at least 20 (i.e., moderate depression) and no greater than 34 (i.e., severe depression) at screen and baseline visit
- Young Mania Rating Scale (YMRS) score < 12 at screen and baseline visit
- currently treated with a lithium preparation (carbonate or citrate) at stable dose for at least 4 wks with level >0.4 and <1.0; and/or valproate at stable dose for at least 4 wks at level >60 and <110; and/or other atypical antipsychotic at stable dose for at least 4 weeks (at least minimum FDA-labeled dose).
Exclusion:
- Psychotic features in the current episode, as assessed by YMRS item #8>6
- felt by the study clinician to require inpatient hospitalization for adequate management
- more than 3 failed pharmacologic interventions in the current major depressive episode, exclusive of primary mood stabilizer
- current substance use disorder other than nicotine, by SCID-I/P
- pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
- women who are breastfeeding
- serious suicide or homicide risk, as assessed by evaluating clinician
- other unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease, based on review of medical history, physical examination, and screening laboratory tests
- patients who have taken an investigational psychotropic drug within the last 30 days
- patients receiving additional anticonvulsant, antipsychotic, or antidepressant within 1 week prior to study entry
- patients requiring continued treatment with excluded medications (see below).
Excluded medications: other statins, which could influence Wnt signaling; any other drug known to interact with simvastatin, including potent inhibitors/inducers of CYP3A4 such as itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, voriconazole, cyclosporine or danazol; gemfibrozil or other lipid-lowering drugs that can cause myopathy when given alone; amiodarone, ranolazine, verapamil, diltiazem, or amlodipine; niacin; digoxin; coumarin anticoagulants; colchicine; nefazodone; protease inhibitors including ritonavir, indinavir, nelfinavir, or saquinavir.
Allowed: benzodiazepines and sedative-hypnotic agents if dosage has been stable for 2 weeks prior to study entry; thyroid or estrogen replacement provided dosage has been stable for 1 month; antidepressants, antipsychotics, and anticonvulsants provided dosage has been stable for 1 week prior to study entry.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Simvastatin-Simvastatin
Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
|
The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks.
The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect.
Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
|
Experimental: Placebo->Simvastatin
Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
|
The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks.
The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect.
Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks.
Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
|
Comparador de Placebo: Placebo-Placebo
Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
|
Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks.
Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in MADRS (4 Weeks)
Prazo: Baseline vs week 4 (and, for placebo nonresponders in 1st 4 weeks, week 8 vs week 4)
|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) in simvastatin-treated epochs versus placebo-treated epochs
|
Baseline vs week 4 (and, for placebo nonresponders in 1st 4 weeks, week 8 vs week 4)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Roy H Perlis, MD, MSc, Massachusetts General Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Transtornos Bipolares e Relacionados
- Transtorno bipolar
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Antimetabólitos
- Agentes Anticolesterêmicos
- Agentes Hipolipidêmicos
- Agentes Reguladores Lipídicos
- Inibidores da hidroximetilglutaril-CoA redutase
- Sinvastatina
Outros números de identificação do estudo
- 2011P002545
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Transtorno bipolar
-
ProgenaBiomeRecrutamentoTranstorno bipolar | Transtorno Bipolar I | Transtorno Bipolar II | Transtorno Bipolar Tipo I | Transtorno Bipolar Leve | Transtorno Bipolar Moderado | Transtorno Bipolar GraveEstados Unidos
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionConcluídoTranstorno Bipolar I | Transtorno Bipolar II | Transtorno Bipolar SOEEstados Unidos
-
Region StockholmKarolinska InstitutetRecrutamentoTranstorno bipolar | Depressão bipolar | Transtorno Bipolar I | Transtorno Bipolar II | Transtorno Afetivo Bipolar; Remissão em | Transtorno Afetivo Bipolar, Atualmente Deprimido, ModeradoSuécia
-
Joshua RosenblatRecrutamentoTranstorno bipolar | Depressão bipolar | Transtorno Bipolar I | Transtorno Bipolar IICanadá
-
National Human Genome Research Institute (NHGRI)ConcluídoTranstorno Bipolar (DB) | BipolarEstados Unidos
-
Joshua RosenblatRecrutamentoTranstorno bipolar | Depressão bipolar | Transtorno Bipolar I | Transtorno Bipolar IICanadá
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationConcluídoTranstorno bipolar | Depressão bipolar | Transtorno Bipolar I | Transtorno Bipolar I | Transtorno Afetivo BipolarEstados Unidos
-
University Health Network, TorontoConcluídoTranstorno bipolar | Depressão bipolar | Depressão Bipolar I | Depressão Bipolar IICanadá
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoAtivo, não recrutandoTranstorno bipolar | Depressão bipolar | Transtorno Depressivo Maior | Transtorno Bipolar I | Transtorno afetivo | Transtorno Bipolar IIBrasil
-
Medical University of South CarolinaMilken InstituteConcluídoTranstorno bipolar | Transtorno Bipolar I | Transtorno Bipolar IIEstados Unidos